Ultragenyx granted 45,984 restricted stock units to 23 non-executive officers as part of a new employment inducement plan.
Quiver AI Summary
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company specializing in therapies for rare diseases, announced the grant of 45,984 restricted stock units to 23 newly hired non-executive officers as part of their employment inducement plan. This grant, approved by the company's compensation committee, is in accordance with Nasdaq regulations and is effective as of August 16, 2026. The restricted stock units will vest over four years, with 25% vesting each year, contingent upon ongoing employment. Ultragenyx is dedicated to developing innovative treatments for serious genetic diseases, focusing on areas with significant unmet medical needs. For additional information, visit their website.
Potential Positives
- Ultragenyx Pharmaceutical Inc. demonstrated its commitment to attracting top talent by granting 45,984 restricted stock units to 23 newly hired non-executive officers, enhancing its leadership team.
- The use of restricted stock units as an inducement aligns with industry standards and serves to motivate new employees by linking their financial rewards to the company's stock performance.
- The grants are part of a strategic plan under the Ultragenyx Employment Inducement Plan, which reflects the company's growth trajectory and the importance of building a robust workforce in the biopharmaceutical sector.
- Vesting of the stock units over four years encourages long-term commitment from new employees, which can lead to increased stability and continuity within the company.
Potential Negatives
- The grant of 45,984 restricted stock units to 23 newly hired non-executive officers may raise concerns about the company's financial priorities, as it indicates a significant dispersion of equity compensation at a time when stakeholders may be focused on the company's overall financial performance.
- The issuance of stock units could dilute existing shareholders' equity, potentially leading to dissatisfaction among current investors, particularly if the company is not performing well financially.
- The reliance on restricted stock units as inducement for new hires might suggest challenges in attracting talent through traditional compensation methods, which could affect the company's ability to build a strong leadership team.
FAQ
What is the recent stock grant announced by Ultragenyx Pharmaceutical?
Ultragenyx granted 45,984 restricted stock units to 23 newly hired non-executive officers as an employment inducement.
Who approved the stock awards at Ultragenyx?
The stock awards were approved by the compensation committee of Ultragenyx's board of directors.
When was the grant date for the restricted stock units?
The grant date for the restricted stock units was August 16, 2026.
How do the restricted stock units vest at Ultragenyx?
The restricted stock units vest over four years, with 25% vesting each anniversary, subject to employment status.
What is Ultragenyx Pharmaceutical's focus?
Ultragenyx focuses on developing novel therapies for rare and ultra-rare genetic diseases with high unmet medical needs.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$RARE Insider Trading Activity
$RARE insiders have traded $RARE stock on the open market 21 times in the past 6 months. Of those trades, 0 have been purchases and 21 have been sales.
Here’s a breakdown of recent trading of $RARE stock by insiders over the last 6 months:
- EMIL D KAKKIS (President & CEO) sold 54,404 shares for an estimated $1,240,411
- HOWARD HORN (Chief Financial Officer) has made 0 purchases and 8 sales selling 33,457 shares for an estimated $825,618.
- KARAH HERDMAN PARSCHAUER (EVP and Chief Legal Officer) has made 0 purchases and 5 sales selling 21,460 shares for an estimated $487,890.
- ERIK HARRIS (EVP & Chief Commercial Officer) sold 10,539 shares for an estimated $240,289
- JOHN RICHARD PINION (See Remarks) sold 10,029 shares for an estimated $228,661
- ERIC CROMBEZ (EVP and Chief Medical Officer) has made 0 purchases and 2 sales selling 7,373 shares for an estimated $168,847.
- SHEHNAAZ SULIMAN sold 5,740 shares for an estimated $144,188
- CORAZON (CORSEE) D. SANDERS sold 2,000 shares for an estimated $50,100
- THEODORE ALAN HUIZENGA (SVP, Chief Accounting Officer) sold 1,632 shares for an estimated $37,209
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
$RARE Congressional Stock Trading
Members of Congress have traded $RARE stock 1 times in the past 6 months. Of those trades, 1 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $RARE stock by members of Congress over the last 6 months:
- REPRESENTATIVE GILBERT RAY CISNEROS, JR. purchased up to $15,000 on 03/03.
To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard. You can access data on congressional stock trades through the Quiver Quantitative API Congress trades endpoint.
$RARE Hedge Fund Activity
We have seen 173 institutional investors add shares of $RARE stock to their portfolio, and 180 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- RTW INVESTMENTS, LP added 4,148,100 shares (+113.7%) to their portfolio in Q2 2026, for an estimated $138,505,059
- BLACKROCK, INC. added 3,354,678 shares (+46.0%) to their portfolio in Q2 2026, for an estimated $112,012,698
- BAKER BROS. ADVISORS LP removed 2,772,692 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $58,087,897
- ASSENAGON ASSET MANAGEMENT S.A. added 2,057,951 shares (+1030.4%) to their portfolio in Q1 2026, for an estimated $43,114,073
- SUVRETTA CAPITAL MANAGEMENT, LLC removed 2,019,000 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $42,298,050
- AQR CAPITAL MANAGEMENT LLC added 1,982,785 shares (+43.3%) to their portfolio in Q2 2026, for an estimated $66,205,191
- CITADEL ADVISORS LLC removed 1,904,960 shares (-90.0%) from their portfolio in Q2 2026, for an estimated $63,606,614
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
$RARE Price Targets
Multiple analysts have issued price targets for $RARE recently. We have seen 9 analysts offer price targets for $RARE in the last 6 months, with a median target of $43.0.
Here are some recent targets:
- Luca Issi from RBC Capital set a target price of $40.0 on 07/07/2026
- Kristen Kluska from Cantor Fitzgerald set a target price of $96.0 on 05/21/2026
- Laura Chico from Wedbush set a target price of $26.0 on 05/08/2026
- Debjit Chattopadhyay from Guggenheim set a target price of $43.0 on 05/08/2026
- Benjamin Burnett from Wells Fargo set a target price of $47.0 on 05/06/2026
- Eliana Merle from Barclays set a target price of $43.0 on 04/29/2026
- Jeffrey Hung from Morgan Stanley set a target price of $67.0 on 04/16/2026
Full Release
NOVATO, Calif., Aug. 25, 2026 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for rare and ultra-rare diseases, today reported the grant of 45,984 restricted stock units of the company’s common stock to 23 newly hired non-executive officers of the company. The awards were approved by the compensation committee of the company’s board of directors and granted under the Ultragenyx Employment Inducement Plan, with a grant date of August 16, 2026, as an inducement material to the new employees entering into employment with Ultragenyx in accordance with Nasdaq Listing Rule 5635(c)(4).
The restricted stock units vest over four years, with 25% of the underlying shares vesting on each anniversary of the grant date, subject to the employee being continuously employed by the company as of such vesting dates.
About Ultragenyx Pharmaceutical Inc.
Ultragenyx is a biopharmaceutical company committed to bringing novel products to patients for the treatment of serious rare and ultrarare genetic diseases. The company has built a diverse portfolio of approved therapies and product candidates aimed at addressing diseases with high unmet medical need and clear biology for treatment, for which there are typically no approved therapies treating the underlying disease.
The company is led by a management team experienced in the development and commercialization of rare disease therapeutics. Ultragenyx’s strategy is predicated upon time- and cost-efficient drug development, with the goal of delivering safe and effective therapies to patients with the utmost urgency.
For more information on Ultragenyx, please visit the company's website at: www.ultragenyx.com .
Contact Ultragenyx
Investors & Media
Joshua Higa
(415) 475-6370
